Treatment of osteoporosis in children with glucocorticoid-treated diseases

Faienza, Maria Felicia; Luce, Vincenza; Lonero, Antonella; Ventura, Alessandro; Colaianni, Graziana; Colucci, Silvia; Grano, Maria; Brunetti, Giacomina

doi:10.1586/17446651.2014.936384

Cited by 4 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glucocorticoid (GC)-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. GCs decrease bone formation by promoting apoptosis of osteoblasts and osteocytes and increasing bone resorption [7,8]. Furthermore, GCs reduce intestinal absorption of calcium and increase its renal excretion; thus, fractures may occur in 30-50% of patients on chronic GC therapy [9].…”

Section: Introductionmentioning

confidence: 99%

Bone Remodeling Markers in Children with Acute Lymphoblastic Leukemia after Intensive Chemotherapy: The Screenshot of a Biochemical Signature

Muggeo¹,

Grassi²,

D’Ascanio

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Purpose: to investigate the effects of intensive chemotherapy and glucocorticoid (GC) treatment on bone remodeling markers in children with acute lymphoblastic leukemia (ALL). Methods: A cross-sectional study was carried out in 39 ALL children (aged 7.64 ± 4.47) and 49 controls (aged 8.7 ± 4.7 years). Osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL), osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX), bone alkaline phosphatase (bALP), tartrate-resistant acid phosphatase 5b (TRACP5b), procollagen type I N-terminal propeptide (P1NP), Dickkopf-1 (DKK-1), and sclerostin were assessed. Statistical analysis was conducted using the principal component analysis (PCA) to study patterns of associations in bone markers. Results: ALL patients showed significantly higher OPG, RANKL, OC, CTX, and TRACP5b than the controls (p ≤ 0.02). Considering ALL group, we found a strong positive correlation among OC, TRACP5b, P1NP, CTX, and PTH (r = 0.43–0.69; p < 0.001); between CTX and P1NP (r = 0.5; p = 0.001); and between P1NP and TRAcP (r = 0.63; p < 0.001). The PCA revealed OC, CTX, and P1NP as the main markers explaining the variability of the ALL cohort. Conclusions: Children with ALL showed a signature of bone resorption. The assessment of bone biomarkers could help identify ALL individuals who are most at risk of developing bone damage and who need preventive interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Bone Remodeling Markers in Children with Acute Lymphoblastic Leukemia after Intensive Chemotherapy: The Screenshot of a Biochemical Signature

Muggeo¹,

Grassi²,

D’Ascanio

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…A decrease of bone mineral density (BMD) has been reported in numerous pediatric diseases that require GCs, both as long term replacement therapy, such as 21-hydroxylase deficiency (21-OHD), and as treatment of acute phase, such as asthma, systemic lupus erythematosus, juvenile rheumatoid arthritis, inflammatory bowel disease, organ transplantation, and steroid sensitive nephrotic syndrome [ 22 ]. In particular, in 21-OHD patients on chronic GC therapy, the high osteoclastogenic potential of peripheral blood mononuclear cells has been reported [ 100 ].…”

Section: Introductionmentioning

confidence: 99%

Bone-Immune Cell Crosstalk: Bone Diseases

Mori

D’Amelio

Faccio

et al. 2015

Journal of Immunology Research

Self Cite

View full text Add to dashboard Cite

Bone diseases are associated with great morbidity; thus, the understanding of the mechanisms leading to their development represents a great challenge to improve bone health. Recent reports suggest that a large number of molecules produced by immune cells affect bone cell activity. However, the mechanisms are incompletely understood. This review aims to shed new lights into the mechanisms of bone diseases involving immune cells. In particular, we focused our attention on the major pathogenic mechanism underlying periodontal disease, psoriatic arthritis, postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, metastatic solid tumors, and multiple myeloma.

show abstract

Crocin promotes osteogenesis differentiation of bone marrow mesenchymal stem cells

Qin

Wang

et al. 2020

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

Treatment of osteoporosis in children with glucocorticoid-treated diseases

Cited by 4 publications

References 95 publications

Bone Remodeling Markers in Children with Acute Lymphoblastic Leukemia after Intensive Chemotherapy: The Screenshot of a Biochemical Signature

Bone Remodeling Markers in Children with Acute Lymphoblastic Leukemia after Intensive Chemotherapy: The Screenshot of a Biochemical Signature

Bone-Immune Cell Crosstalk: Bone Diseases

Crocin promotes osteogenesis differentiation of bone marrow mesenchymal stem cells

Contact Info

Product

Resources

About